Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to protect kidneys in rare genetic disease

NCT ID NCT06274489

Completed Disease control Sponsor: Calliditas Therapeutics AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug, setanaxib, in 20 people with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if the drug is safe and can help preserve kidney function when added to standard care. Participants took either setanaxib or a placebo for 24 weeks, and researchers monitored side effects and kidney health through blood and urine tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alport syndrome hereditary nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPORT SYNDROME

Contacts and locations

Locations

  • AP-HP Hopital Necker-Enfants Malades

    Paris, 75015, France

  • Fakultni Nemocnice Hradec Kralove

    Hradec Králové, Czechia

  • Fakultni Nemocnice Olomouc

    Olomouc, Czechia

  • Fundacio Puigvert

    Barcelona, 08025, Spain

  • Great Ormond Street Hospital for Children

    London, WC1N 3JH, United Kingdom

  • Hospital Clinic Barcelona

    Barcelona, 08036, Spain

  • Hospital Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Usera, 28041, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, 14004, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Virgen de las Nieves

    Granada, 18014, Spain

  • Institut Klinicke a Experimentalni Mediciny

    Prague, Czechia

  • Medizinische Universitaet Wien

    Vienna, State of Vienna, 1090, Austria

  • Nottingham City Hospital

    Nottingham, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, NW3 2QG, United Kingdom

  • Royal Manchester Children's Hospital

    Manchester, M13 9WL, United Kingdom

  • Vseobecna Fakultni Nemocnice v Praze

    Prague, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.